The 503B Bulks List Rule: What Happens to Your Compounded Prescription
The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the pathway that made large-scale compounding possible. Here is what that means for patients currently on a compounded prescription.
The short version
- On April 30, 2026 the FDA said it wants to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, concluding there is no longer a clinical need for outsourcing facilities to compound these drugs from bulk substance.
- The proposal closes both the bulks-list route and the shortage-list route — the two legal doorways that made mass compounding possible from 2022 onward.
- It does not, by itself, end all compounding. Patient-specific 503A compounding with documented medical necessity sits on different legal footing.
- If you are on a compounded prescription today, the practical risk is supply disruption, not a sudden legal problem for you personally.
For four years the compounded GLP-1 market ran on a narrow legal opening. Brand-name semaglutide and tirzepatide went into shortage in 2022, and federal law lets compounders produce copies of drugs on the FDA's shortage list. When shortages were declared resolved, that doorway shut — but a second one stayed open. Bulk drug substances that appear on the 503B Bulks List can be compounded by registered outsourcing facilities regardless of shortage status. That list is what the FDA is now moving against.
What the proposed rule actually says
On April 30, 2026, the agency stated it wants to end most compounding of semaglutide, tirzepatide, and liraglutide, on the finding that there is no longer a clinical need for certain compounded versions of these medications. The mechanism is specific: barring 503B outsourcing facilities from bulk compounding these three molecules, and removing both the bulks-list and shortage-list pathways that had permitted it.
The clinical-need finding is the load-bearing part. Under the Federal Food, Drug, and Cosmetic Act, a substance earns a place on the bulks list because compounding it serves a need that approved products do not meet. With brand-name injectables in stable supply and two oral GLP-1s now approved — the Wegovy pill in December 2025 and Foundayo in April 2026 — the agency's position is that the need argument has run out of road.
This is a proposed rule, not an overnight ban, and it targets 503B outsourcing facilities compounding from bulk substance. Patient-specific compounding at a 503A pharmacy, where a clinician documents why an individual patient cannot use the approved product, rests on a different section of the statute. Expect that distinction to become the entire battleground.
Why the additive workaround probably will not save it
The industry's main response to the end of the shortage was reformulation. Market research firm IQVIA reported that more than 80% of compounded semaglutide and tirzepatide prescriptions included supplemental ingredients such as B vitamins or levocarnitine, and noted that these additives may function as a rationale for continued compounding now that supply issues are resolved. The researchers were direct about the possibility that some compounders use these modifications to differentiate their products or navigate regulatory ambiguity.
The FDA has not been subtle in response. In warning letters sent to telehealth companies in February 2026, the agency pushed back on marketing claims implying compounded products had been FDA-approved or evaluated for safety and effectiveness when they had not. Adding a vitamin does not create a new clinical justification on its own; a documented reason a specific patient needs the variation does.
Providers with a path forward on either side of this rule
Every provider below is a paid partner. Pricing changes frequently — confirm current cost on the provider's own page before you enrol.
Semaglutide injection through a licensed US telehealth network. Injectable only — no oral formulation offered.
See Embody pricing Paid partner linkMarketplace for cash-pay appointments with clinicians who prescribe FDA-approved brand-name medication only — Rybelsus, the oral Wegovy pill, and Foundayo. No compounded product.
See Sesame Care pricing Paid partner linkOffers both injectable and sublingual/buccal compounded options. Sublingual semaglutide runs roughly $199/mo, tirzepatide roughly $299/mo.
See SkinnyRx pricing Paid partner linkWhat changes for you, and when
If you are mid-titration on a compounded product
Nothing legally changes for you as the patient. Enforcement runs against pharmacies and prescribers, not people taking medication. The realistic risk is that your supplier stops filling, and you find out with a few weeks of notice or less. That has already happened repeatedly through this cycle.
If you are shopping now
Weigh the durability of the supply chain, not just the monthly price. A provider that already offers brand-name product, or that has an announced pathway to it, carries less disruption risk than one whose entire model depends on bulk-compounded semaglutide.
If you are price-sensitive
The gap that made compounding attractive has narrowed sharply. Compounded products generally ran in the range of roughly $150 to $300 per month against branded pricing above $1,000. That branded number is no longer the relevant comparison. Foundayo's self-pay price starts at $149 per month for the lowest dose, eligible commercially insured patients may pay as little as $25 per month with a savings card, and Medicare Part D access at $50 per month opened on July 1, 2026.
Ask your provider two questions in writing: what is your plan if the bulks-list rule is finalised, and can you transfer me to an FDA-approved product without a new intake. A provider that cannot answer both is a provider you should be prepared to leave.
The litigation running alongside
Regulatory action is only one pressure source. Novo Nordisk sued Hims & Hers for patent infringement in February 2026 and has said it has now filed 132 suits across 40 states, winning 44 permanent injunctions. Eli Lilly sued the compounders Strive Pharmacy and Empower in April 2025, then four telehealth companies weeks later. Even if the rulemaking stalls, the civil docket is narrowing the market on its own.
Two of the largest telehealth players have already moved. Hims & Hers announced in March 2026 it would make Novo Nordisk's semaglutide injections and pills available to subscribers while continuing to offer compounded GLP-1s where a provider determines one is clinically necessary. Ro struck a deal with Eli Lilly in April 2026 to prescribe Foundayo alongside semaglutide pills and injections and tirzepatide injections. When the two biggest distributors hedge toward brand, that is a signal about where the rest of the market is heading.
The honest bottom line
Mass-market compounded GLP-1s were a product of a supply emergency. The emergency ended, and the regulatory scaffolding built for it is being dismantled deliberately. A narrower form of compounding will survive for patients with a genuine, documented reason the approved product does not work for them. If that is not you, plan for a transition rather than hoping the current arrangement holds.
Sources
- US Food and Drug Administration, proposed rule on 503B Bulks List status for semaglutide, tirzepatide, and liraglutide, April 30, 2026.
- Medscape, coverage of the FDA proposal to end mass GLP-1 compounding, May 1, 2026.
- Pharmacy Times, reporting on the FDA's move to close bulks-list and shortage-list pathways.
- IQVIA analysis of supplemental ingredients in compounded semaglutide and tirzepatide prescriptions.
- FDA press announcement on the approval of Foundayo (orforglipron), April 1, 2026.
- AJMC, reporting on Foundayo pricing tiers and savings card eligibility.